CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial.
C Michael GibsonSyed Hassan A KazmiSerge KorjianGerald ChiAdam T PhillipsSahar Memar MontazerinDanielle DuffyBo ZhengMark HeiseCharles LissLawrence I DeckelbaumSamuel D WrightAndreas GillePublished in: Journal of cardiovascular pharmacology and therapeutics (2022)
Among patients with AMI, impaired CEC was rapidly elevated by CSL112 infusions in a dose-dependent fashion, along with an increase in apoA-I plasma concentrations. Findings from the current sub-study of the AEGIS-I support a potential atheroprotective benefit of CSL112 for AMI patients.
Keyphrases
- acute myocardial infarction
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- endothelial cells
- prognostic factors
- clinical trial
- percutaneous coronary intervention
- heart failure
- risk assessment
- left ventricular
- study protocol
- atrial fibrillation
- acute coronary syndrome
- patient reported
- phase iii
- induced pluripotent stem cells